Everett Rand Sutherland - 30 Jun 2025 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Reporting relationship: Director
Issuer ticker: KRYS
Reported as of: 30 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jun 2025, 18:18:43 UTC
Prior SEC filing: 07 Feb 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Krish Krishnan, as attorney-in-fact for Everett Rand Sutherland

Key filing fact

Everett Rand Sutherland filed Form 4 for Krystal Biotech, Inc. (KRYS) on 30 Jun 2025.

Key facts

This page summarizes Everett Rand Sutherland's Form 4 filing for Krystal Biotech, Inc. (KRYS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jun 2025, 18:18.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001852880 Primary reporting owner

Relationship: Director
Address: C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH
Signature: /s/ Krish Krishnan, as attorney-in-fact for Everett Rand Sutherland
Signature date: 30 Jun 2025

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KRYS transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period.